Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients

Abstract Aims Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long‐term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular remodelling and improvi...

Full description

Bibliographic Details
Main Authors:	Liu Yang, Min Zhang, Zhiheng Hao, Nan Wang
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Series:	ESC Heart Failure
Subjects:	Atrial fibrillation Sacubitril/valsartan Atrial remodelling AF recurrence Pulmonary vein isolation
Online Access:	https://doi.org/10.1002/ehf2.13937

Similar Items

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
by: Ya Suo, et al.
Published: (2019-10-01)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
by: Qingsong Chen, et al.
Published: (2022-05-01)

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice
by: Satoshi Iwamiya, et al.
Published: (2024-01-01)

Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan
by: Michele Correale, et al.
Published: (2023-01-01)

Valsartan Reduced Atrial Fibrillation Susceptibility by Inhibiting Atrial Parasympathetic Remodeling through MAPKs/Neurturin Pathway
by: Lei Liu, et al.
Published: (2015-07-01)

The Role of Atrial Remodelling in Atrial Fibrillation
by: Ignatius Yansen, et al.
Published: (2013-06-01)

Impact of right atrial structural remodeling on recurrence after ablation for atrial fibrillation
by: Takahito Takagi, et al.
Published: (2021-06-01)

The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator
by: Vincenzo Russo, et al.
Published: (2020-04-01)

Immune remodeling and atrial fibrillation
by: Yajun Yao, et al.
Published: (2022-07-01)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System
by: Fedor Simko, et al.
Published: (2022-07-01)

Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up
by: Carla Paolini, et al.
Published: (2021-08-01)

Echocardiographic parameters indicating left atrial reverse remodeling after catheter ablation for atrial fibrillation
by: Eleonora Angelini, et al.
Published: (2023-12-01)

Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation
by: Christopher X. Wong, et al.
Published: (2024-01-01)

Left Atrial Tachycardia After Pulmonary Vein Isolation for Atrial Fibrillation
by: Kenichi Hashimoto, MD, et al.
Published: (2005-01-01)

Atrial late potentials are associated with atrial fibrillation recurrence after catheter ablation
by: Daiki Saito, et al.
Published: (2022-12-01)

Long-Term Changes in the Biomarkers of Left Atrial Fibrosis after Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation
by: Lilla Szuromi, et al.
Published: (2023-06-01)

Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Ruxin Wang, et al.
Published: (2022-07-01)

Effect of sacubitril/valsartan on sinus rhythm maintenance after catheter ablation in patients with persistent atrial fibrillation without reduced ejection fraction heart failure: a study protocol for a multi-center, open-label, randomized, controlled, superiority clinical trial
by: Ruowu Qiu, et al.
Published: (2024-01-01)

Sacubitril/Valsartan Improves Left Atrial and Ventricular Strain and Strain Rate in Patients with Heart Failure with Reduced Ejection Fraction
by: Pedro Garcia Brás, et al.
Published: (2023-04-01)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
by: Reza Mohebi, et al.
Published: (2023-10-01)

Persistence of left atrial abnormalities despite left atrial volume normalization after successful ablation of atrial fibrillation
by: Hiroshi Kawakami, et al.
Published: (2021-10-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Albumin as a Prognostic Marker for Atrial Fibrillation Recurrence following Cryoballoon Ablation of Pulmonary Venous
by: Nili Schamroth Pravda, et al.
Published: (2022-12-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Roles and significance of CaMKⅡ and PLB in atrial remodeling in patients with atrial fibrillation
by: CAO Zhezhe, et al.
Published: (2019-02-01)

Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy
by: Hyue-Mee Kim, et al.
Published: (2021-04-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Early markers of atrial fibrillation recurrence after pulmonary vein isolation
by: Eva A. H. Lanters, et al.
Published: (2020-04-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Redistribution of adipose tissue is associated with left atrial remodeling and dysfunction in patients with atrial fibrillation
by: Qian Chen, et al.
Published: (2022-08-01)

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

A Comparison of Regional Classification Strategies Implemented for the Population Based Approach to Modelling Atrial Fibrillation
by: Jordan Elliott, et al.
Published: (2021-07-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
by: Wioletta Sacharczuk, et al.
Published: (2023-04-01)

A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure
by: Carles Moliner-Abós, et al.
Published: (2021-02-01)

Targeting Autophagy in Atrial Fibrillation
by: Qiang Ye, et al.
Published: (2023-10-01)